Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Repligen To Acquire A Novozymes Facility

by Michael McCoy
November 7, 2011 | A version of this story appeared in Volume 89, Issue 45

Repligen is acquiring a Novozymes plant in Lund, Sweden, that manufactures both growth factors used in mammalian cell culture and Protein A affinity ligands used to make monoclonal antibodies. Repligen is paying about $23 million plus potential milestone payments of almost $6 million. The Swedish business is expected to have sales of more than $16 million this year. Repligen, which already sells four forms of Protein A, says the transaction will elevate it into a leading supplier of products for manufacturing biologic drugs.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.